Inactive Instrument

Press Releases CytRx Corporation Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Mar. 27	LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 11	Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol	DJ

FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C Results in XOMA Making a $1 Million Milestone Payment to LadRx	Jan. 12	AQ
LadRx Issues 2024 Update to Shareholders	Jan. 09	BU
LadRx: Q3 Earnings Snapshot	Nov. 14	AQ
LadRx : Modification to Rights of Security Holders - Form 8-K	23-09-11	PU
LadRx: Q2 Earnings Snapshot	23-08-14	AQ
Investor Presentation: July 2023	23-07-14	PU
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation	23-06-22	BU
LadRx Announces Reverse Stock Split Effective as of May 17, 2023	23-05-18	BU
LadRx Announces Reverse Stock Split	23-05-10	BU
LadRx Highlights Patent Issued for Its LADR Technology	23-03-27	BU
LadRx Announces Review of Strategic Alternatives and Provides Corporate Updates	23-03-15	BU
Investor Presentation: November 2022	22-11-17	PU
LadRx Corporation Issues Corporate Update for 3Q22	22-11-17	BU
LadRx Corporation Announces OTCQB Ticker Change to LADX	22-10-05	BU
Investor Presentation: September 2022	22-09-26	PU
CytRx Corporation Relaunches as LadRx Corporation	22-09-23	BU
CYTRX CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-09-23	AQ
Investor Presentation: August 2022	22-09-10	PU
European Patent Office Awards CytRx Key Patent	22-09-07	BU
CYTRX CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-08-11	AQ

No results for this search